MiMedx Group MDXG Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81%-0.9pp | 82.6%-0.2pp | 82%-1.4pp | 81.5%-2.0pp | 81.9%-1.6pp | |
| Operating margin | 10.2%-5.1pp | 15.3%-1.6pp | 13.7%-4.8pp | 11.8%-6.8pp | 15.3%+0.2pp | |
| Net margin | 7.9%-3.5pp | 11.6%-0.6pp | 10.4%-15.4pp | 8.8%-17.3pp | 11.4%-10.3pp | |
| EBITDA margin | 13.1%-4.5pp | 18.8%+0.2pp | 16.9%-3.1pp | 14.7%-5.3pp | 17.6%+1.3pp | |
| Free cash flow margin | 17.8%-0.5pp | 17.4%-1.1pp | 17%+0.7pp | 15.7%+1.4pp | 18.3%+8.1pp | |
| Returns | ||||||
| Return on equity | 13.8%-8.6pp | 21.6%-3.7pp | 19.4%-77.6pp | 16.7%— | 22.4%— | |
| Return on assets | 10.6%-5.7pp | 16%-0.8pp | 14.5%-26.4pp | 12.3%-31.4pp | 16.3%-20.9pp | |
| Return on invested capital | 26.6%-6.1pp | 41.4%+3.1pp | 34.9%— | 26.4%— | 32.7%— | |
| Efficiency | ||||||
| Asset turnover | 1.3×-0.1× | 1.4×0.0× | 1.4×-0.2× | 1.4×-0.3× | 1.4×-0.3× | |
| Inventory turnover | 2.9×+0.3× | 3×+0.3× | 2.8×+0.2× | 2.7×0.0× | 2.6×-0.2× | |
| Liquidity | ||||||
| Current ratio | 5.4×+0.7× | 4.3×+0.1× | 4.4×+0.3× | 4.4×+0.5× | 4.7×+1.4× | |
| Quick ratio | 4.8×+0.7× | 3.9×+0.2× | 3.9×+0.4× | 3.9×+0.7× | 4.1×+1.4× | |
| Cash ratio | 3.6×+1.1× | 2.6×+0.3× | 2.5×+0.3× | 2.4×+0.6× | 2.5×+1.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -2.8×-1.4× | -1.8×-0.6× | -1.9×-0.8× | -1.9×-1.2× | -1.4×-0.9× | |
| Interest coverage | 11.9×— | 21.8×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $1.64+20.8% | $1.71+32.3% | $1.60+30.8% | $1.45+28.5% | $1.35+30.5% | |
| Valuation | ||||||
| Market capitalization | $567.48M-33.9% | $1B-29.1% | $1.03B+19.0% | $880.3M-13.9% | $1.12B-1.0% | |
| Enterprise value | $425.3M-44.8% | $859.06M-35.6% | $908.89M+13.9% | $779.9M-19.9% | $1.03B-6.4% | |
| Price / earnings | 18.5×-2.9× | 20.6×-12.7× | 25.3×+15.5× | 27.4×+15.9× | 27.9×+12.3× | |
| Price / sales | 1.5×-1.0× | 2.4×-1.7× | 2.6×+0.1× | 2.4×-0.6× | 3.2×-0.2× | |
| Price / book | 2.3×-1.9× | 3.9×-3.4× | 4.3×-0.5× | 4.1×-2.0× | 5.5×-1.7× | |
| EV / EBITDA | 8.3×-4.1× | 10.9×-9.6× | 13.7×+2.0× | 14.6×+0.3× | 16.6×-3.5× | |
| EV / sales | 1.1×-1.1× | 2.1×-1.8× | 2.3×0.0× | 2.1×-0.7× | 2.9×-0.4× | |
| Free cash flow yield | 12.2%+4.7pp | 7.3%+2.7pp | 6.5%0.0pp | 6.5%+1.7pp | 5.8%+2.7pp | |
| Earnings yield | 5.4%+0.7pp | 4.8%+1.8pp | 4%-6.2pp | 3.7%-5.0pp | 3.6%-2.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are MiMedx Group's profit margins?
- MiMedx Group (MDXG) runs a 81.0% gross margin and a 10.2% operating margin, with a 7.9% net margin.
- Where do MiMedx Group's ratios come from?
- Every ratio is computed from MiMedx Group's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
